fda glp-1 enforcement news Safety Check How FDA's Action Against Non-FDA-Approved

Compounding refers to medications prepared by specialty pharmacies that create customized versions of branded drugs at significantly lower cost

Another review found that people taking the maximum dose of Qsymia lost roughly 10% of their body weight over 56 weeks (just over one year), and the weight loss helped improve certain risk factors for heart disease and type 2 diabetes

Acting essentially is what youre saying

Critical limitations include: Heterogeneity : Different strains, doses, and formulations make comparisons difficult Small effect sizes : Weight changes are typically modest and may not be clinically significant Short duration : Most studies last 12 weeks or less, providing no data on sustained effects Publication bias : Negative studies may be underreported There is no high-quality evidence that probiotic supplements can replicate the substantial weight loss achieved with prescription medications like semaglutide or tirzepatide

Duke-Cohan, and A

Crucially, the $50 monthly copay for GLP-1s will not count toward a patient's Part D deductible, or the $2,100 annual out-of-pocket cap on prescription drug costs, said Rachel Schmidt, a research professor at Georgetown University's McCourt School of Public Policy